药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2026/03/24 – 2026/03/30
- New acceptances this week
- 365
- Drugs with new generic filings (by drug name, de-duplicated)
- 39
- Accepted this week, now under review
- 79
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
365filings, 48 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 225 |
| New drug | 61 |
| Generic | 48 |
| Import re-registration | 13 |
| Unspecified | 10 |
| Import | 8 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 190 |
| TCM | 142 |
| 治疗用生物制品 | 29 |
| Biologic | 2 |
| 预防用生物制品 | 2 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
39 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 羟考酮纳洛酮缓释片 | 3 | 1 | 3 |
| 2 | 他克莫司缓释胶囊 | 2 | 1 | 6 |
| 3 | 利格列汀二甲双胍缓释片 | 2 | 1 | 4 |
| 4 | 培美曲塞二钠注射液 | 2 | 1 | 2 |
| 5 | 头孢地尼颗粒 | 2 | 1 | 3 |
| 6 | 头孢托仑匹酯颗粒 | 2 | 1 | 18 |
| 7 | 巴瑞替尼片 | 2 | 1 | 32 |
| 8 | 苯磺酸美洛加巴林片 | 2 | 1 | 58 |
| 9 | 二十碳五烯酸乙酯软胶囊 | 1 | 1 | 25 |
| 10 | 佩玛贝特片 | 1 | 1 | 25 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
219 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 东阿阿胶股份有限公司 | 15 | 13 | 0 |
| 2 | 伊春康尔心药业有限公司 | 11 | 10 | 0 |
| 3 | 吉林敖东延边药业股份有限公司 | 6 | 6 | 0 |
| 4 | 河南诺美药业有限公司 | 6 | 6 | 0 |
| 5 | 哈药集团生物工程有限公司 | 6 | 2 | 0 |
| 6 | 江西心正药业有限责任公司 | 5 | 5 | 0 |
| 7 | Takeda Development Center Americas Inc. | 5 | 1 | 0 |
| 8 | 江苏费森尤斯医药用品有限公司 | 4 | 4 | 0 |
| 9 | 津药达仁堂集团股份有限公司达仁堂制药厂 | 4 | 4 | 0 |
| 10 | AstraZeneca AB | 4 | 3 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
81 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/03/30Generic · Class 3 | 利格列汀二甲双胍缓释片CYHS2600746 | 南通联亚药业股份有限公司 |
| 2026/03/30Generic · Class 3 | 利格列汀二甲双胍缓释片CYHS2600745 | 南通联亚药业股份有限公司 |
| 2026/03/30New drug · Class 2.1 | 热毒宁颗粒CXZS2600018 | 江苏康缘药业股份有限公司 |
| 2026/03/30New drug · Class 1 | 注射用QLF4113CXSL2600363 | 齐鲁制药有限公司 |
| 2026/03/30New drug · Class 1.2 | 猴痘mRNA疫苗CXSL2600362 | 江苏中慧元通生物科技股份有限公司; 易慧生物技术(上海)有限公司 |
| 2026/03/30New drug · Class 1 | 注射用BL-M14D1CXSL2600361 | 成都百利多特生物药业有限责任公司; 四川百利药业有限责任公司 |
| 2026/03/30New drug · Class 1 | IBI354CXSL2600360 | 信达生物医药科技（杭州）有限公司 |
| 2026/03/30New drug · Class 1 | ICP-B208CXSL2600359 | 北京诺诚健华医药科技有限公司 |
| 2026/03/30New drug · Class 1 | ADRX-0405CXSL2600358 | 上海德烽药业有限公司 |
| 2026/03/30New drug · Class 2.2;2.4 | DMET25001缓释片CXHL2600397 | 武汉龙升医药科技有限责任公司 |
| 2026/03/30New drug · Class 2.2;2.4 | DMET25001缓释片CXHL2600396 | 武汉龙升医药科技有限责任公司 |
| 2026/03/30New drug · Class 1 | 注射用WP1302CXHL2600395 | 百明信康生物技术（浙江）股份有限公司 |
| 2026/03/28Import · Class 1 | AZD2936JXSL2600087 | AstraZeneca AB; AstraZeneca Global R&D (China) Co. Ltd. |
| 2026/03/28Generic · Class 3 | 磷酸奥司他韦颗粒CYHS2600737 | 湖南普道医药技术有限公司; 湖南九典制药股份有限公司 |
| 2026/03/28New drug · Class 3.1 | 麦门冬汤颗粒CXZS2600017 | 广东一方制药有限公司 |
| 2026/03/28New drug · Class 1.1 | 香术调脾和中颗粒CXZL2600032 | 山西省中医药研究院（山西省中医院） |
| 2026/03/28New drug · Class 2.2 | 特瑞普利单抗注射液CXSL2600357 | 上海君实生物医药科技股份有限公司 |
| 2026/03/28New drug · Class 2.2 | 特瑞普利单抗注射液CXSL2600356 | 上海君实生物医药科技股份有限公司 |
| 2026/03/28New drug · Class 1 | GT201注射液CXSL2600355 | 北京沙砾生物医药股份有限公司 |
| 2026/03/28New drug · Class 1 | SCTB10注射液CXSL2600354 | 神州细胞工程有限公司 |
| 2026/03/28New drug · Class 1 | JYP0035胶囊CXHL2600394 | 嘉越（成都）医药科技有限公司 |
| 2026/03/28New drug · Class 1 | JYP0015片CXHL2600393 | 广州嘉越医药科技股份有限公司 |
| 2026/03/28New drug · Class 1 | JYP0015片CXHL2600392 | 广州嘉越医药科技股份有限公司 |
| 2026/03/28New drug · Class 1 | WXFL10030390片CXHL2600391 | 上海嘉坦医药科技有限公司 |
| 2026/03/28New drug · Class 1 | JYP0015片CXHL2600390 | 广州嘉越医药科技股份有限公司 |
| 2026/03/28New drug · Class 1 | WXFL10030390片CXHL2600389 | 上海嘉坦医药科技有限公司 |
| 2026/03/28New drug · Class 1 | JYP0015片CXHL2600388 | 广州嘉越医药科技股份有限公司 |
| 2026/03/27Import · Class 2.2 | 阿伏利尤单抗注射液JXSL2600086 | AstraZeneca AB; AstraZeneca Investment (China) Co. Ltd. |
| 2026/03/27Import · Class 1 | 贝普若韦生注射液JXHS2600033 | GlaxoSmithKline Trading Services Limited; GLAXO OPERATIONS UK LTD TRADING AS GLAXO WELLCOME OPERATIONS; GlaxoSmithKline (China) Investment Company Limited |
| 2026/03/27Import · Class 1 | Brenipatide注射液JXHL2600094 | Eli Lilly and Company; Lilly Suzhou Pharmaceutical Co. Ltd. |
51 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.